PWM
NTLA icon

Perigon Wealth Management’s Intellia Therapeutics NTLA Stock Holding History

Perigon Wealth Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-509
Closed -$28K – 847
2020
Q4 		$28K Buy
+509
New +$18.5K ﹤0.01% 926
2017
Q4 		– Sell
-4,693
Closed -$117K – 653
2017
Q3 		$117K Buy
+4,693
New +$88.4K 0.04% 245

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Chevy Chase Trust
Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Perigon Wealth Management's NTLA Position: Q1 2021 in Review

Perigon Wealth Management sold out of Intellia Therapeutics (NTLA) in Q1 2021, closing a stake of 509 shares — an estimated $28K sold.

Perigon Wealth Management first reported a position in NTLA in Q3 2017 and held it in 2 quarters. The position peaked at $117K in Q3 2017. 260 funds tracked by Wall St. Rank hold NTLA as of Q1 2021.

  • Perigon Wealth Management reported no remaining Intellia Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Perigon Wealth Management sold 509 Intellia Therapeutics shares in Q1 2021, an estimated $28K.
  • Perigon Wealth Management first reported a position in Intellia Therapeutics in Q3 2017 and held it in 2 quarters.
  • Perigon Wealth Management's Intellia Therapeutics position peaked at $117K in Q3 2017.
  • 260 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2021.

Based on Perigon Wealth Management's 13F filing for Q1 2021, filed 17 May 2021.